| |
著者: K B Pittman, I N Olver, B Koczwara, D Kotasek, W K Patterson, D M Keefe, C S Karapetis, F X Parnis, S Moldovan, S J Yeend, T J Price, Adelaide Cancer Trials and Education Collaborative (ACTEC)
雑誌名: Br J Cancer. 2006 Nov 20;95(10):1309-13. doi: 10.1038/sj.bjc.6603440. Epub 2006 Oct 31.
Abstract/Text
Cancer of unknown primary site (CUP) represents up to 5% of all cancer diagnoses and is associated with poor survival. We have performed a prospective multicentre phase 2 trial to evaluate efficacy and toxicity of the combination of gemcitabine (G) and carboplatin (C) for patients with CUP. Patients with histologically confirmed metastatic carcinoma in which the primary site of cancer was not evident after prospectively designated investigation and who had ECOG performance status 0-2 were treated with G 1000 mg m(-2) intravenously (i.v.) days 1 and 8, and C AUC 5 i.v. on day 8 every 3 weeks to a maximum of nine cycles. The primary end points were response rate, and toxicity, with secondary end points of progression-free survival and overall survival. Fifty-one (23 male, 27 female) patients were enrolled (one patient ineligible), with a median age of 69 years (range 41-83 years). Fifty patients were evaluable for toxicity and 46 patients were evaluable for efficacy. The overall response rate to the GC regimen was 30.5%. With a median follow-up of 24 months, the median progression-free survival was 18 weeks (4.2 months) and the median overall survival was 34 weeks (7.8 months). The frequency of grade 3 or 4 toxicity was low. Nausea/vomiting was the most common side effect, but was usually only mild in severity. Uncomplicated neutropenia (14%), thrombocytopenia (10%) and anaemia (8%) were the most common causes of grade 3-4 toxicity. The regimen was very well tolerated, particularly in the elderly. The GC regimen is an active regimen in CUP with excellent tolerability and should be considered particularly for elderly patients with CUP.
PMID 17088914 Br J Cancer. 2006 Nov 20;95(10):1309-13. doi: 10.1038/sj.bjc.6603440. Epub 2006 Oct 31.
|
